colchicine: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
colchicine: clinical details
Prescribing considerations
- Confirm the indication and review prescription, non-prescription and herbal products because colchicine has a narrow therapeutic window.
- Assess renal and hepatic function, age, frailty, gastrointestinal or cardiovascular disease, blood abnormalities and interacting medicines.
- Counsel patients about gastrointestinal toxicity, blood-disorder symptoms and muscle symptoms.
Contraindications and cautions
- Hypersensitivity to colchicine or an excipient.
- Severe blood dyscrasia.
- Severe renal or hepatic impairment and haemodialysis.
- Renal or hepatic impairment with a P-glycoprotein inhibitor or strong CYP3A4 inhibitor.
- Pregnancy, breastfeeding, or childbearing potential without effective contraception, according to the selected product's SmPC.
Monitoring
- Periodic full blood counts because severe marrow suppression may develop gradually or suddenly.
- Monitor renal and hepatic function where impairment or relevant interacting treatment is present.
- Arrange urgent haematological investigation for fever, stomatitis, sore throat, bruising or prolonged bleeding.
- Investigate new muscle pain or weakness and review concomitant medicines.
Clinical pharmacology
Colchicine modifies microtubule function and inflammatory-cell activity. It accumulates in leucocytes, undergoes partial hepatic metabolism and biliary handling, and is eliminated through faecal and renal routes. It is a CYP3A4 and P-glycoprotein substrate.
Formulation and product differences
- The selected product is an oral, uncoated tablet containing lactose.
- Store it in its original packaging to protect it from light.
- Appearance, excipients and packaging can differ between products; check the product-specific SmPC or leaflet.
colchicine preparations and strengths
Tablet
Route: Oral
Strengths: 500 micrograms
colchicine interactions
Colchicine is a CYP3A4 and P-glycoprotein substrate. Inhibiting either pathway can substantially increase exposure and cause severe or fatal toxicity.
Macrolide antibiotics, including clarithromycin and erythromycin
Can markedly increase colchicine exposure and toxicity; the combination requires urgent clinical review.
Azole antifungals, including ketoconazole, itraconazole and voriconazole
Can increase colchicine concentrations and the risk of life-threatening toxicity.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.